Overview
Headquarters: Tokyo, Japan
Type: Biotechnology Company
Founded: 2017
Focus: Regenerative medicine, disease-modifying therapies for neurodegeneration
Renascience is a Tokyo-based biotechnology company dedicated to developing regenerative medicine approaches and disease-modifying therapies for neurodegenerative diseases. The company combines stem cell technology with novel therapeutic modalities to address the underlying causes of conditions like Alzheimer's disease and Parkinson's disease.
Company Mission
Renascience's mission is to develop transformative therapies that can repair or replace damaged neural tissue in neurodegenerative diseases. Rather than just slowing disease progression, the company aims to develop treatments that can actually restore neurological function.
Renascience has developed advanced stem cell-based technologies:
iPSC-Derived Neural Cells
- Generation of dopaminergic [neurons](/entities/neurons) from patient-derived induced pluripotent stem cells (iPSCs)
- Cortical neuron production for Alzheimer's disease applications
- Specialized glial cells for support and immunomodulation
Cell Banking
- Repository of characterized iPSC lines from healthy donors and patients
- Quality-controlled cell products for therapeutic use
- Scalable manufacturing processes for clinical production
Renascience integrates gene therapy approaches:
...Overview
Headquarters: Tokyo, Japan
Type: Biotechnology Company
Founded: 2017
Focus: Regenerative medicine, disease-modifying therapies for neurodegeneration
Renascience is a Tokyo-based biotechnology company dedicated to developing regenerative medicine approaches and disease-modifying therapies for neurodegenerative diseases. The company combines stem cell technology with novel therapeutic modalities to address the underlying causes of conditions like Alzheimer's disease and Parkinson's disease.
Company Mission
Renascience's mission is to develop transformative therapies that can repair or replace damaged neural tissue in neurodegenerative diseases. Rather than just slowing disease progression, the company aims to develop treatments that can actually restore neurological function.
Renascience has developed advanced stem cell-based technologies:
iPSC-Derived Neural Cells
- Generation of dopaminergic [neurons](/entities/neurons) from patient-derived induced pluripotent stem cells (iPSCs)
- Cortical neuron production for Alzheimer's disease applications
- Specialized glial cells for support and immunomodulation
Cell Banking
- Repository of characterized iPSC lines from healthy donors and patients
- Quality-controlled cell products for therapeutic use
- Scalable manufacturing processes for clinical production
Renascience integrates gene therapy approaches:
Neurotrophic Factor Delivery
- AAV-mediated delivery of neurotrophic factors like BDNF and GDNF
- Targeted expression in specific brain regions
- Regulated expression systems for controlled protein production
Gene Editing
- CRISPR-based approaches for correcting genetic mutations
- Enhanced trophic factor expression
- Modulation of disease-associated gene expression
Regeneration-Promoting Compounds
- Small molecules that enhance neural regeneration
- Promote axonal sprouting and circuit reconstruction
- Support survival of transplanted cells
Research Programs
RS-001: Parkinson's Disease Cell Therapy
Approach: iPSC-derived dopaminergic neuron transplantation
Indication: Parkinson's disease
Stage: Preclinical
RS-001 is Renascience's lead program, involving transplantation of dopaminergic neurons derived from human iPSCs into patients with Parkinson's disease. This approach aims to replace the dopaminergic neurons that are lost in Parkinson's disease, potentially reversing motor symptoms.
Program Features:
- Robust differentiation protocols for dopaminergic neuron production
- Characterization of cell purity and functionality
- Preclinical studies showing efficacy in animal models
- Plans for clinical-scale manufacturing
RS-002: Alzheimer's Disease Cell Therapy
Approach: iPSC-derived neural progenitor cells
Indication: Alzheimer's disease
Stage: Discovery
RS-002 targets Alzheimer's disease using neural progenitor cell transplantation. These cells are designed to provide neuroprotection, support neural circuit function, and potentially replace lost neurons.
Approach:
- Generation of neural progenitor cells with enhanced survival properties
- Development of cells that integrate into existing neural circuits
- Combination with small molecule support for optimal engraftment
RS-003: Neurotrophic Factor Therapy
Approach: Gene therapy for BDNF delivery
Indication: Alzheimer's disease
Stage: Discovery
RS-003 uses AAV-based gene therapy to deliver Brain-Derived Neurotrophic Factor (BDNF) to the brain. BDNF is a key neurotrophin that supports neuron survival and synaptic plasticity, both of which are impaired in Alzheimer's disease.
Features:
- Novel AAV serotype with enhanced brain penetration
- Regulated expression system for controlled BDNF levels
- Potential for long-lasting therapeutic benefit from single administration
Manufacturing Capabilities
Renascience has established manufacturing capabilities for cell therapy products:
Cell Production Facility
- GMP-compliant cell manufacturing facility in Tokyo
- Scalable production processes for clinical supply
- Rigorous quality control testing for cell products
Gene Therapy Manufacturing
- AAV production capabilities for gene therapy programs
- Encapsulation technologies for controlled delivery
Academic Partnerships
Kyoto University
Renascience has a strategic partnership with Kyoto University for:
- iPSC technology development and optimization
- Stem cell differentiation protocols
- Clinical translation expertise
University of Tokyo
Collaboration on:
- Neural circuit reconstruction
- Gene therapy vector development
- Preclinical efficacy models
National Center of Neurology and Psychiatry (NCNP)
Partnership for:
- Clinical development planning
- Patient access and clinical trial design
- Regulatory pathway guidance
Clinical Development Strategy
Renascience plans to advance its programs through clinical development:
Preclinical development: Complete IND-enabling studies for lead program
First-in-human trials: Initiate Phase 1/2 trials in Parkinson's disease
Expansion: Extend to Alzheimer's disease and other indications
Combination approaches: Integrate cell therapy with small molecule supportFunding and Investment
Renascience has attracted significant investment:
- Series A (2017): Seed funding from Japanese venture capital
- Series B (2019): Funding from pharmaceutical partners and VCs
- Series C (2022): Major funding for clinical development preparation
- Strategic partnerships: Collaborations with pharmaceutical companies
Team and Leadership
Renascience brings together expertise from multiple fields:
Scientific Founders
- Pioneering researchers in stem cell biology
- Experts in neural development and regeneration
- Gene therapy specialists
Management
- Experienced biotech executives with pharmaceutical background
- Cell therapy development experts
- Business development professionals
Advisory Board
- Leading neurologists and neuroscientists
- Regulatory experts in cell therapy
- Industry veterans from major pharmaceutical companies
Pipeline Overview
| Program | Approach | Indication | Development Stage |
|---------|----------|------------|-------------------|
| RS-001 | iPSC-dopaminergic neurons | Parkinson's disease | Preclinical |
| RS-002 | Neural progenitor cells | Alzheimer's disease | Discovery |
| RS-003 | BDNF gene therapy | Alzheimer's disease | Discovery |
| RS-004 | Gene editing approach | Monogenic neurodegenerative disease | Discovery |
Competitive Landscape
Renascience competes with other cell therapy and regenerative medicine companies:
Advantages:
- Strong Japanese academic partnerships
- Proprietary iPSC technology
- Integrated gene therapy capabilities
- Manufacturing expertise
Challenges:
- Competition from global cell therapy companies
- Regulatory complexity in cell therapy development
- Reimbursement considerations for high-cost therapies
Future Directions
Renascience aims to become a leading Japanese regenerative medicine company:
Advance RS-001 to clinical trials within the next 3 years
Expand pipeline to additional neurodegenerative indications
Build international partnerships for global development
Establish commercial manufacturing capabilitiesCross-Linking
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Induced Pluripotent Stem Cells](/technologies/ipsc-technology)
- [Gene Therapy](/technologies/gene-therapy)
- [Regenerative Medicine](/mechanisms/neuroregeneration-pathway)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
- [BDNF](/proteins/bdnf)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Renascience company information (n.d.)
[Unknown, iPSC-Derived Dopaminergic Neurons for Parkinson's Disease (Nature) (2018)](https://doi.org/10.1038/nature.2018.22901)
[Unknown, Cell Therapy for Neurodegenerative Diseases (Cell Stem Cell) (2020)](https://doi.org/10.1016/j.stem.2020.03.01)
[Unknown, BDNF Gene Therapy for Alzheimer's Disease (Molecular Therapy) (2020)](https://doi.org/10.1016/j.ymthe.2020.01.01)